 |
| Founders |
Genexis Biotech will utilise the capital to expand its bioreactor capacity, build downstream processing infrastructure, and launch a new line of smart proteins and recombinant peptidase enzymes. It will also use the funds to strengthen quality control, regulatory compliance, and expand its sales and distribution channels.
Speaking on the investment, Mihir Joshi, Managing Director of GVFL, said, “Genexis is solving a critical gap in India’s biotech value chain by enabling high-quality, animal-origin-free protein production at scale. The company’s R&D strength, infrastructure, and early traction position it well to serve a growing demand across biopharma, food-tech, and life sciences. We are pleased to support Genexis in this transformative journey.”
In the past 12 months, Genexis has developed a range of recombinant growth factors, peptidases, and cell culture reagents. It has established strategic partnerships with pharmaceutical companies, biotech startups, and research laboratories. The company’s certified Class 10,000 manufacturing facility is now operational, with plans underway for a GMP-compliant unit.
Vipul Kumar, Director at Genexis Biotech, said, “At Genexis Biotech, we are building India’s deep-tech backbone for animal-origin-free protein production. The seed round marks a key milestone in our journey and will accelerate our path to scale, enabling sustainable innovation across healthcare, food, and bio-industrial sectors.”
Genexis Biotech recently introduced recombinant peptidases such as amino peptidase and enterokinase, and is preparing to launch recombinant transferrin and albumin. Genexis also signed an MoU with the Gujarat government for scaling up recombinant protein manufacturing and showcased its portfolio at Global Bio-India 2024. It has secured multiple clients and has received orders for alternative protein formulation projects.
In the next phase of growth, Genexis Biotech aims to enter the regulated biotech export market, form strategic collaborations with Contract Development and Manufacturing Organisations (CDMOs), academic labs and biopharma companies. Its plans also include developing encapsulated growth factor formulations for the cosmetics industry.
About GVFL: GVFL is an Ahmedabad, Gujarat based Venture Capital Fund. With over 150+ total investments and 90+ successful exits, It has been instrumental in nurturing and scaling innovative startups across various sectors. GVFL has a diverse portfolio, investing in sectors such as agritech, healthtech, fintech, deep tech, clean tech, defense tech, enterprise tech, and consumer brands.
About Genexis Biotech: Genexis Biotech is a pioneering bio-manufacturing company developing high-quality, animal-origin-free proteins using recombinant technology and precision fermentation. With a robust in-house R&D and ISO-compliant infrastructure, the company serves key sectors like biopharma, regenerative medicine, cell culture media, and cultivated meat. Genexis aims to democratise access to safe, ethical, and scalable biomolecules while contributing to a greener and self-reliant biotech ecosystem.
Speaking on the investment, Mihir Joshi, Managing Director of GVFL, said, “Genexis is solving a critical gap in India’s biotech value chain by enabling high-quality, animal-origin-free protein production at scale. The company’s R&D strength, infrastructure, and early traction position it well to serve a growing demand across biopharma, food-tech, and life sciences. We are pleased to support Genexis in this transformative journey.”
In the past 12 months, Genexis has developed a range of recombinant growth factors, peptidases, and cell culture reagents. It has established strategic partnerships with pharmaceutical companies, biotech startups, and research laboratories. The company’s certified Class 10,000 manufacturing facility is now operational, with plans underway for a GMP-compliant unit.
Vipul Kumar, Director at Genexis Biotech, said, “At Genexis Biotech, we are building India’s deep-tech backbone for animal-origin-free protein production. The seed round marks a key milestone in our journey and will accelerate our path to scale, enabling sustainable innovation across healthcare, food, and bio-industrial sectors.”
Genexis Biotech recently introduced recombinant peptidases such as amino peptidase and enterokinase, and is preparing to launch recombinant transferrin and albumin. Genexis also signed an MoU with the Gujarat government for scaling up recombinant protein manufacturing and showcased its portfolio at Global Bio-India 2024. It has secured multiple clients and has received orders for alternative protein formulation projects.
In the next phase of growth, Genexis Biotech aims to enter the regulated biotech export market, form strategic collaborations with Contract Development and Manufacturing Organisations (CDMOs), academic labs and biopharma companies. Its plans also include developing encapsulated growth factor formulations for the cosmetics industry.
About GVFL: GVFL is an Ahmedabad, Gujarat based Venture Capital Fund. With over 150+ total investments and 90+ successful exits, It has been instrumental in nurturing and scaling innovative startups across various sectors. GVFL has a diverse portfolio, investing in sectors such as agritech, healthtech, fintech, deep tech, clean tech, defense tech, enterprise tech, and consumer brands.
About Genexis Biotech: Genexis Biotech is a pioneering bio-manufacturing company developing high-quality, animal-origin-free proteins using recombinant technology and precision fermentation. With a robust in-house R&D and ISO-compliant infrastructure, the company serves key sectors like biopharma, regenerative medicine, cell culture media, and cultivated meat. Genexis aims to democratise access to safe, ethical, and scalable biomolecules while contributing to a greener and self-reliant biotech ecosystem.
IndianWeb2.com is an independent digital media platform for business, entrepreneurship, science, technology, startups, gadgets and climate change news & reviews.
No comments
Post a Comment